1019 related articles for article (PubMed ID: 33622224)
1. SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
Mohammed MEA
Curr Mol Med; 2022; 22(1):50-66. PubMed ID: 33622224
[TBL] [Abstract][Full Text] [Related]
2. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
3. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
[TBL] [Abstract][Full Text] [Related]
4. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
5. Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins.
Li Y; Xu Z; Lei Q; Lai DY; Hou H; Jiang HW; Zheng YX; Wang XN; Wu J; Ma ML; Zhang B; Chen H; Yu C; Xue JB; Zhang HN; Qi H; Guo SJ; Zhang Y; Lin X; Yao Z; Sheng H; Sun Z; Wang F; Fan X; Tao SC
Cell Rep; 2021 Jul; 36(2):109391. PubMed ID: 34242574
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
Jung LS; Gund TM; Narayan M
Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
[TBL] [Abstract][Full Text] [Related]
7. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
8. In silico discovery of antigenic proteins and epitopes of SARS-CoV-2 for the development of a vaccine or a diagnostic approach for COVID-19.
Can H; Köseoğlu AE; Erkunt Alak S; Güvendi M; Döşkaya M; Karakavuk M; Gürüz AY; Ün C
Sci Rep; 2020 Dec; 10(1):22387. PubMed ID: 33372181
[TBL] [Abstract][Full Text] [Related]
9. Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice.
Silvas JA; Vasquez DM; Park JG; Chiem K; Allué-Guardia A; Garcia-Vilanova A; Platt RN; Miorin L; Kehrer T; Cupic A; Gonzalez-Reiche AS; Bakel HV; García-Sastre A; Anderson T; Torrelles JB; Ye C; Martinez-Sobrido L
J Virol; 2021 Aug; 95(17):e0040221. PubMed ID: 34133899
[TBL] [Abstract][Full Text] [Related]
10. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
van de Leemput J; Han Z
Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
[TBL] [Abstract][Full Text] [Related]
11. Targeting viral proteins for restraining SARS-CoV-2: focusing lens on viral proteins beyond spike for discovering new drug targets.
Yang T; Wang SC; Ye L; Maimaitiyiming Y; Naranmandura H
Expert Opin Drug Discov; 2023 Mar; 18(3):247-268. PubMed ID: 36723288
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns.
Redondo N; Zaldívar-López S; Garrido JJ; Montoya M
Front Immunol; 2021; 12():708264. PubMed ID: 34305949
[TBL] [Abstract][Full Text] [Related]
14. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation.
Bai Z; Cao Y; Liu W; Li J
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200602
[TBL] [Abstract][Full Text] [Related]
15. The percentages of SARS-CoV-2 protein similarity and identity with SARS-CoV and BatCoV RaTG13 proteins can be used as indicators of virus origin.
Mohammed MEA
J Proteins Proteom; 2021; 12(2):81-91. PubMed ID: 33850392
[TBL] [Abstract][Full Text] [Related]
16. Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins.
Pribanić Matešić M; Kučan Brlić P; Lenac Roviš T; Mačak Šafranko Ž; Chaouat AE; Miklić K; Malić S; Ivanković N; Schubert M; Bertoglio F; Markotić A; Mandelboim O; Jonjić S; Brizić I
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216036
[TBL] [Abstract][Full Text] [Related]
17. The role of SARS-CoV-2 accessory proteins in immune evasion.
Zandi M; Shafaati M; Kalantar-Neyestanaki D; Pourghadamyari H; Fani M; Soltani S; Kaleji H; Abbasi S
Biomed Pharmacother; 2022 Dec; 156():113889. PubMed ID: 36265309
[TBL] [Abstract][Full Text] [Related]
18. The importance of accessory protein variants in the pathogenicity of SARS-CoV-2.
Hassan SS; Choudhury PP; Dayhoff GW; Aljabali AAA; Uhal BD; Lundstrom K; Rezaei N; Pizzol D; Adadi P; Lal A; Soares A; Mohamed Abd El-Aziz T; Brufsky AM; Azad GK; Sherchan SP; Baetas-da-Cruz W; Takayama K; Serrano-Aroca Ã; Chauhan G; Palu G; Mishra YK; Barh D; Santana Silva RJ; Andrade BS; Azevedo V; Góes-Neto A; Bazan NG; Redwan EM; Tambuwala M; Uversky VN
Arch Biochem Biophys; 2022 Mar; 717():109124. PubMed ID: 35085577
[TBL] [Abstract][Full Text] [Related]
19. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Shifman O; Achdout H; Vitner EB; Israeli O; Milrot E; Stein D; Cohen-Gihon I; Lazar S; Gutman H; Glinert I; Cherry L; Vagima Y; Lazar S; Weiss S; Ben-Shmuel A; Avraham R; Puni R; Lupu E; Bar-David E; Sittner A; Erez N; Zichel R; Mamroud E; Mazor O; Levy H; Laskar O; Yitzhaki S; Shapira SC; Zvi A; Beth-Din A; Paran N; Israely T
Nat Commun; 2020 Dec; 11(1):6402. PubMed ID: 33328475
[TBL] [Abstract][Full Text] [Related]
20. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.
Tabll AA; Shahein YE; Omran MM; Elnakib MM; Ragheb AA; Amer KE
Hum Antibodies; 2021; 29(3):179-191. PubMed ID: 33998533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
